# Sorrect Sequence

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sorrect-sequence

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.correctsequence.com
- Total disclosed funding: $67M
- Latest round: Series A (Aug 8, 2024)
- Investors on record: 7

## About

Established in 2020 and based in Shanghai, China, Sorrect Sequence is a gene technology developer that focuses on the research and development of gene editing technology. The company was co-founded by Prof. Jia Chen, Prof. Li Yang, Prof. Hao Yin, and Prof. Beiyang. The company is headquartered in Shanghai, with R&D and manufacturing centers in Shanghai and a clinical registration and operations center in Beijing. The company's CEO, Xiaodun Mou, holds a Ph.D. in Chemical Biology from Rensselaer Polytechnic Institute in the U.S. and has nearly 20 years of experience in CMC process development for antibodies and fusion proteins. The company's self-developed CS-101 injectable drug was approved in April 2024 for IND. In August 2024, it raised a series A+ funding for over CNY 100 million.

The company's business is the research and development of innovative gene editing therapies. The company's self-developed core product is the Translational Gene Editor tBE (Transformer Base Editor). Its products are used in the fields of genetic, metabolic and cardiovascular diseases.

Sorrect Sequence generates revenue by offering licensing agreements for its proprietary gene editing technology, conducting collaborative research with pharmaceutical partners, and driving the commercialization of its therapies through clinical trials.

The company will use the series A+ funding to accelerate CS-101 clinical research and commercialization advancement, as well as to support the clinical translation of the in vivo therapeutic pipeline and drive gene editing products to market.

## Funding rounds

- Series A, Aug 8, 2024, $14M — Lilly Asia Ventures, Boyu Capital, New Alliance Capital, HSG, Wanwu Shengzhang Capital, Fortera Capital
- Series A, Nov 8, 2021, $47M — Lilly Asia Ventures, Boyu Capital, New Alliance Capital, TF Capital, HSG, Wanwu Shengzhang Capital
- Angel, Dec 30, 2020, $6.1M — New Alliance Capital, TF Capital, HSG, Wanwu Shengzhang Capital

## Investors

- New Alliance Capital (https://capitalatlas.ai/funds/new-alliance-capital) — Angel, Series A
- TF Capital — Angel, Series A
- HSG (https://capitalatlas.ai/funds/hsg) — Angel, Series A
- Wanwu Shengzhang Capital (https://capitalatlas.ai/funds/wanwu-shengzhang-capital) — Angel, Series A
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series A
- Boyu Capital (https://capitalatlas.ai/funds/boyu-capital) — Series A
- Fortera Capital (https://capitalatlas.ai/funds/fortera-capital) — Series A